These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
485 related articles for article (PubMed ID: 30227225)
1. Differential anti-microbial secondary metabolites in different ESKAPE pathogens explain their adaptation in the hospital setup. Tiwari V; Meena K; Tiwari M Infect Genet Evol; 2018 Dec; 66():57-65. PubMed ID: 30227225 [TBL] [Abstract][Full Text] [Related]
2. Norfloxacin salts of carboxylic acids curtail planktonic and biofilm mode of growth in ESKAPE pathogens. Lowrence RC; Ramakrishnan A; Sundaramoorthy NS; Shyam A; Mohan V; Subbarao HMV; Ulaganathan V; Raman T; Solomon A; Nagarajan S J Appl Microbiol; 2018 Feb; 124(2):408-422. PubMed ID: 29178633 [TBL] [Abstract][Full Text] [Related]
3. Functional Differences between E. coli and ESKAPE Pathogen GroES/GroEL. Sivinski J; Ambrose AJ; Panfilenko I; Zerio CJ; Machulis JM; Mollasalehi N; Kaneko LK; Stevens M; Ray AM; Park Y; Wu C; Hoang QQ; Johnson SM; Chapman E mBio; 2021 Jan; 12(1):. PubMed ID: 33436430 [TBL] [Abstract][Full Text] [Related]
4. Detection of ESKAPE Bacterial Pathogens at the Point of Care Using Isothermal DNA-Based Assays in a Portable Degas-Actuated Microfluidic Diagnostic Assay Platform. Renner LD; Zan J; Hu LI; Martinez M; Resto PJ; Siegel AC; Torres C; Hall SB; Slezak TR; Nguyen TH; Weibel DB Appl Environ Microbiol; 2017 Feb; 83(4):. PubMed ID: 27986722 [TBL] [Abstract][Full Text] [Related]
5. Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010-2020 decade in India. Kharat AS; Makwana N; Nasser M; Gayen S; Yadav B; Kumar D; Veeraraghavan B; Mercier C Int J Antimicrob Agents; 2024 May; 63(5):107125. PubMed ID: 38431109 [TBL] [Abstract][Full Text] [Related]
6. In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens. Younis W; AbdelKhalek A; Mayhoub AS; Seleem MN Curr Pharm Des; 2017; 23(14):2147-2157. PubMed ID: 28190396 [TBL] [Abstract][Full Text] [Related]
7. In Vitro Emergence of High Persistence upon Periodic Aminoglycoside Challenge in the ESKAPE Pathogens. Michiels JE; Van den Bergh B; Verstraeten N; Fauvart M; Michiels J Antimicrob Agents Chemother; 2016 Aug; 60(8):4630-7. PubMed ID: 27185802 [TBL] [Abstract][Full Text] [Related]
8. Plasmid profiles among some ESKAPE pathogens in a tertiary care centre in south India. Ragupathi NKD; Bakthavatchalam YD; Mathur P; Pragasam AK; Walia K; Ohri VC; Veeraraghavan B Indian J Med Res; 2019 Feb; 149(2):222-231. PubMed ID: 31219087 [TBL] [Abstract][Full Text] [Related]
9. Human Salivary Protein Histatin 5 Has Potent Bactericidal Activity against ESKAPE Pathogens. Du H; Puri S; McCall A; Norris HL; Russo T; Edgerton M Front Cell Infect Microbiol; 2017; 7():41. PubMed ID: 28261570 [TBL] [Abstract][Full Text] [Related]
10. Navigating ESKAPE Pathogens: Considerations and Caveats for Animal Infection Models Development. Yu H; Xu Y; Imani S; Zhao Z; Ullah S; Wang Q ACS Infect Dis; 2024 Jul; 10(7):2336-2355. PubMed ID: 38866389 [TBL] [Abstract][Full Text] [Related]
11. Eliciting antibiotics active against the ESKAPE pathogens in a collection of actinomycetes isolated from mountain soils. Zhu H; Swierstra J; Wu C; Girard G; Choi YH; van Wamel W; Sandiford SK; van Wezel GP Microbiology (Reading); 2014 Aug; 160(Pt 8):1714-1725. PubMed ID: 24794971 [TBL] [Abstract][Full Text] [Related]
12. Effect of secondary metabolite of Actinidia deliciosa on the biofilm and extra-cellular matrix components of Acinetobacter baumannii. Tiwari V; Tiwari D; Patel V; Tiwari M Microb Pathog; 2017 Sep; 110():345-351. PubMed ID: 28705748 [TBL] [Abstract][Full Text] [Related]
13. Bactericidal efficacy of atmospheric pressure non-thermal plasma (APNTP) against the ESKAPE pathogens. Flynn PB; Higginbotham S; Alshraiedeh NH; Gorman SP; Graham WG; Gilmore BF Int J Antimicrob Agents; 2015 Jul; 46(1):101-7. PubMed ID: 25963338 [TBL] [Abstract][Full Text] [Related]
14. Clonal dispersion of Acinetobacter baumannii in an intensive care unit designed to patients COVID-19. Durán-Manuel EM; Cruz-Cruz C; Ibáñez-Cervantes G; Bravata-Alcantará JC; Sosa-Hernández O; Delgado-Balbuena L; León-García G; Cortés-Ortíz IA; Cureño-Díaz MA; Castro-Escarpulli G; Vélez-Reséndiz JM; Bello-López JM J Infect Dev Ctries; 2021 Jan; 15(1):58-68. PubMed ID: 33571146 [TBL] [Abstract][Full Text] [Related]
16. Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients. Jain M; Sharma A; Sen MK; Rani V; Gaind R; Suri JC Microb Pathog; 2019 Mar; 128():75-81. PubMed ID: 30562602 [TBL] [Abstract][Full Text] [Related]
17. Update on the main MDR pathogens: prevalence and treatment options. Esposito S; De Simone G Infez Med; 2017 Dec; 25(4):301-310. PubMed ID: 29286008 [TBL] [Abstract][Full Text] [Related]
20. Surveillance and comparison of antimicrobial susceptibility patterns of ESKAPE organisms isolated from patients with bacteraemia in South Africa, 2016 - 2017. Ismail H; Lowman W; Govind CN; Swe Swe-Han K; Maloba MRB; Bamford C; Perovic O S Afr Med J; 2019 Nov; 109(12):934-940. PubMed ID: 31865955 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]